LSE - Delayed Quote GBp
Faron Pharmaceuticals Oy (FARN.L)
210.21
-2.29
(-1.08%)
As of 9:28:02 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
18,673
18,673
28,567
27,426
21,109
Operating Income
-18,673
-18,673
-28,567
-27,426
-21,109
Net Non Operating Interest Income Expense
-7,242
-4,366
-2,341
-1,349
-230
Pretax Income
-25,915
-25,915
-30,944
-28,730
-21,178
Tax Provision
5
5
0
0
16
Net Income Common Stockholders
-25,920
-25,920
-30,944
-28,730
-21,194
Diluted NI Available to Com Stockholders
-25,920
-25,920
-30,944
-28,730
-21,194
Basic EPS
-0.29
--
-0.40
-0.43
-0.35
Diluted EPS
-0.29
--
-0.40
-0.43
-0.35
Basic Average Shares
88,518.65
--
78,306.99
66,480.36
61,056.62
Diluted Average Shares
88,518.65
--
78,306.99
66,480.36
61,056.62
Total Operating Income as Reported
-18,673
-18,673
-28,568
-27,426
-21,108
Rent Expense Supplemental
--
246
320
114
7
Total Expenses
18,673
18,673
28,567
27,426
21,109
Net Income from Continuing & Discontinued Operation
-25,920
-25,920
-30,944
-28,730
-21,194
Normalized Income
-25,920
-23,564.80
-30,902
-28,730
-21,194
Interest Income
434
93
230
11
2
Interest Expense
7,676
3,944
2,125
1,373
215
Net Interest Income
-7,242
-4,366
-2,341
-1,349
-230
EBIT
-18,239
-21,971
-28,819
-27,357
-20,963
EBITDA
-17,925
-21,656
-28,473
-27,057
-20,657
Reconciled Depreciation
314
315
346
300
306
Net Income from Continuing Operation Net Minority Interest
-25,920
-25,920
-30,944
-28,730
-21,194
Total Unusual Items Excluding Goodwill
--
-2,944
-42
--
--
Total Unusual Items
--
-2,944
-42
--
--
Normalized EBITDA
-17,925
-18,712
-28,431
-27,057
-20,657
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
-588.80
0
0
0
12/31/2021 - 11/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NANOFH.HE Nanoform Finland Oyj
0.9880
+1.02%
24H.F Hansa Biopharma AB (publ)
2.2840
-2.14%
HAMLET-B.ST Hamlet BioPharma AB ser. B
4.0550
-0.61%
BIOBV.HE Biohit Oyj
2.6300
-1.13%
HRTIS.HE Herantis Pharma Oyj
1.3900
+3.73%
BVXP.L Bioventix PLC
2,735.00
-0.55%
AURA Aura Biosciences, Inc.
4.9700
-9.14%
AVCT.L Avacta Group Plc
35.65
+6.42%
CGEM Cullinan Therapeutics, Inc.
7.70
-1.91%
QTTB Q32 Bio Inc.
1.5700
+1.95%